In our study, we found that prolonged sorafenib exposure altered HCC microenvironment towards an immune-resistant state, and anti-PD-1 antibody showed no obvious influence on tumor growth of sorafenib-treating tumors. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.